Malaria kills at least one million people each year, mostly children - a death every 30 seconds. Almost one half of the world population is at risk from malaria. Antimalarial drugs are the only means for the treatment of about 500 million annual global malaria cases. Because of prevalent drug-resistance it is extremely urgent to identify new drug targets. Many proteins involved in eukaryotic signal transduction and cell cycle progression undergo post-translational lipid modification by a prenyl group. Protein prenyltransferases, which catalyze the post-translational prenyl modification, have been established as a target for anticancer therapy. Research done in our laboratory has demonstrated recently that prenyl modification of proteins could be a novel target for the development of antimalarial drugs.The goal of this study is to understand the molecular mechanism of protein prenylation in Plasmodium. The key to use of prenyltransferase inhibitors for the pharmacological intervention is a thorough understanding of the in vivo prenylation pathways in the malaria parasite. Knowledge of the physiological functions of the cellular protein substrates of malarial prenyltransferases is an important first step in the elucidation of the mechanism of antimalarial action of inhibitors of protein prenylation. The research described in this thesis revealed the evidence for the existence of farnesylated and geranylgeranylated malaria parasite proteins. The study shows that the dynamics of protein prenylation changes with the intraerythrocytic development cycle of the parasite. We detected that prenylated proteins in the 50 kDa range were mostly farnesylated and that the proteins in the 22-25 kDa range were mostly geranylgeranylated. The prenylation of P. falciparum proteins is inhibited by prenyltransferase inhibitors. We have also demonstrated unique features of protein prenylation in P. falciparum compared to the human host such as farnesylation of proteins are sensitive to inhibition by geranylgeranyltransferase inhibitors.. In-silico search of the malarial genome sequence identified potential protein prenyltransferase substrates. One of these substrates is a SNARE protein Ykt6 homologue. The malarial Ykt6 was recombinantly expressed and subjected to an in-vitro prenylation assay. We showed that the recombinant Ykt6 was indeed a substrate for the malarial prenyltransferase.

No / Extracts of Erythrina addisoniae are frequently used in the traditional medicine of Western Africa, but insufficient information about active compounds is available. From the stem bark of E. addisoniae, three (1, 2, 4) and three known (3, 5, 6) flavanones were isolated: addisoniaflavanones I and II, containing either a 2″,3″-epoxyprenyl moiety (1) or a 2″,3″-dihydroxyprenyl moiety (2) were shown to be highly toxic (MTT assay: EC50 values of 5.25 ± 0.7 and 8.5 ± 1.3 μM, respectively) to H4IIE hepatoma cells. The cytotoxic potential of the other isolated flavanones was weaker (range of EC50 values between 15 and >100 μM). Toxic effects of addisoniaflavanone I and II were detectable after 3 h (MTT assay). Both compounds induced an apoptotic cell death (caspase-3/7 activation, nuclear fragmentation) in the hepatoma cells and, at high concentrations, also necrosis (membrane disruption: ethidium bromide staining). Formation of DNA strand breaks was not detectable after incubation with these compounds (comet assay). In conclusion, the prenylated flavanones addisoniaflavanones I and II may be of interest for pharmacological purposes due to their high cytotoxic and pro-apoptotic potential against hepatoma cells.

Located on the short arm of chromosome 4, there exists a gene, IT15, responsible for the trinucleotide CAG expansion involved in the autosomal dominant neurodegenerative disorder known as Huntington’s disease (HD). The brain region associated with the most atrophy, the striatum, leads to expression of severe motor dysfunction, the hallmark feature of HD. To a lesser degree, the cortex and hippocampus show earlier deterioration indicative of the cognitive deficits that occur prior to motor symptom onset. The brain regions associated with HD-induced neuronal death additionally selectively express the protein Rhes - the combination of Rhes and mutant huntingtin being cytotoxic. Using a 3-nitropropionic acid animal model of HD, we hypothesized that animals with preserved prenylation of Rhes would display cognitive and motor symptomology similar to genetic models of HD while animals administered statins or bisphosphonates would show inhibited Rhes prenylation and delayed cognitive symptoms. Experimental animals, however, did not perform differently than control animals on shallow water variants of the t-maze and MWM.

Résumé : L’expression de surface des récepteurs couplés aux protéines G (GPCRs) est un processus hautement régulé et très important dans le maintien de l’homéostasie cellulaire. En effet, un déséquilibre dans leur niveau d’expression est souvent relié à différentes pathologies comme le cancer, le diabète, l’obésité, les maladies cardiovasculaires et les maladies neurodégénératives. C’est pourquoi la compréhension des mécanismes moléculaires influençant ce phénomène est si importante et nous permettra d’élaborer et/ou d’améliorer les médicaments ciblant la régulation de ce processus. Il est bien connu qu’un des acteurs importants dans le trafic vésiculaire des GPCRs est représenté par la famille des Rab GTPases. Effectivement plusieurs de ces dernières, soit les Rabs 1, 2, 4, 5, 6, 7, 8 et 11 pour ne nommer que les plus connues, modulent l’expression de surface des GPCRs. De plus, certaines études soulèvent la possibilité qu’un GPCR soit lui-même capable de réguler son propre trafic intracellulaire, et ce grâce à son interaction avec les Rab GTPases. Toutefois, le mécanisme emprunté par le GPCR pour atteindre cette fin reste à élucider. Dans le présent travail, je démontre que le GPCR, β2AR, module non seulement la maturation de la petite protéine G Rab11a grâce à son interaction avec la Rab GéranylGéranylTransférase (RGGT), mais influence également son activation en modulant son ubiquitination via son association avec la E3-ubiquitine ligase, HACE1. De plus, je révèle que la sous-unité alpha de la RGGT (RGGTA) accroît significativement la maturation et le transport antérograde du récepteur β2AR, ce qui souligne ainsi un nouveau rôle cellulaire pour cette protéine. L’ensemble des résultats générés appuie l’hypothèse qu’un GPCR puisse contrôler son propre routage intracellulaire, et éclaircit les mécanismes utilisés pour réguler l’activé de la Rab GTPase avec laquelle il interagit. // Abstract : Cell surface expression of G Protein-Coupled Receptors (GPCRs) is a highly regulated and very important phenomenon for keeping cellular homeostasis. In fact, dysregulation of their cell expression is related to many diseases like cancer, neurological disorders, obesity, diabetes and cardiovascular diseases. These facts illustrate how important understanding the molecular mechanisms involved in cell surface transport of those receptors is, which will help us in designing or improving drugs which actually target this pathway. Rab GTPases are proteins known for being essential regulators of GPCR vesicular trafficking. Indeed, an increasing number of studies report the implication of Rab1, 2, 4, 5, 6, 7, 8 and 11 (to cite the most frequently studied) cell surface transport of GPCRs. Moreover, some studies also put forward the possibility that a GPCR might be able to regulate its own cellular trafficking by interacting and controlling activation of Rab GTPases. However, the mechanism involved in this process remains to be clarified. In the present study, I demonstrate that the prototypic GPCR, β2AR, not only modulates prenylation/maturation of the small G protein Rab11a by interacting with Rab GeranylGeranylTransferase (RGGT), but also influences Rab11a activation by modulating its ubiquitination via its association with the E3-ubiquitin ligase, HACE1. Furthermore, I reveal that the α subunit of the RGGT (RGGTA) also promotes the maturation and anterograde transport of the receptor, which highlight a new cellular role for this protein. Altogether, those results support the hypothesis that GPCRs control their own trafficking, and shed light on some of the mechanisms that might be employed by those receptors in activation of Rab GTPases.

La prénylation de type I des protéines correspond à une modification post-traductionnelle faisant intervenir une liaison thioéther entre une cystéine localisée dans un motif CaaX en position C terminale et un groupement prényle en C 15 (farnésyle) ou C 20 (géranylgéranyle). Ces réactions sont catalysées par des protéine prényltransférases (PPTs) appartenant à la même famille fonctionnelle et comprenant la protéine farnésyltransférase (PFT) et géranylgéranyltransférase de type I (PGGT-I). Les plantes se distinguent par une double origine des substrats prényle (farnésyle diphosphate et géranylgéranyle diphosphate) utilisés comme précurseurs pour la biosynthèse des isoprénoïdes. Ces derniers sont biosynthétisés par l'intermédiaire de deux voies métaboliques distinctes, la voie cytosolique du mévalonate (MVA) et la voie plastidiale du méthylérythritol phosphate (MEP). Il est maintenant clair que la géranylgéranylation des protéines végétales dépend de la voie du MEP. Durant ce travail de thèse doctorale une étude comparative des spécificités de substrat a été réalisée. Elle a permis de montrer que la PFT est spécifique de son substrat protéique alors que la PGGT-I est spécifique de son substrat prényle. Ces spécificités peuvent néanmoins être modifiées in vivo, par exemple lors d’une augmentation de la concentration en MVA, suggérant que cette flexibilité des propriétés enzymatiques a un rôle régulateur dans certaines conditions physiologiques. Pour cette raison, nous avons entrepris une caractérisation de la prénylation des protéines dans des plantes de tabac élicitées, qui induisent la synthèse de MVA pour produire le capsidiol, une phytoalexine sesquiterpénique. La biosynthèse de ce métabolite secondaire capsidiol dérivant de la voie du MVA, est dépendante de la prénylation des protéines, notamment de protéines géranylgéranylées d’origine plastidiale. Le monoterpène S-carvone a été identifié comme un inhibiteur de la biosynthèse de capsidiol en interférant avec l’activité des PPTs in vivo. Les travaux ont également permis d’envisager l’existence d’un nouveau mode de prénylation des protéines spécifique aux feuilles. / Type-I protein prenylation is a post-translational modification of a protein bearing a CaaX motif with a prenyl moiety, this by a thioether linkage. The enzymes catalyzing those reactions are called protein prenyltransferase (PPTs). Two enzymes are involved, the protein farnesyltransferase (PFT) and the protein geranylgeranyltransferase type I (PGGT-I). They respectively use farnesyl diphosphate and geranylgeranyl diphosphate as substrate. Those precursors are synthetized in plants by two differentbiosynthetic pathways: the cytosolic mevalonate (MVA) and the plastidial methylerythritol phosphate (MEP) pathways. Protein geranylgeranylation is dependent of the MEP pathway. Those specificities can be modified A comparative analysis of PPTs specificity was done during this PhD thesis, revealing that PFT is specific for its protein substrate, while PGGT-I is specific for its prenyl substrate. But those specificities can be modulated in vivo, for instance by increasing the concentration of MVA. This suggests that the regulation of protein prenylation specificities can become functionally important during physiological processes. For that reason we characterized protein prenylation in elicited tobacco plants, which produce the sesquiterpene phytoalexin capsidiol. This metabolite is synthesized via the MVA pathway, and this process depends of protein prenylation, in particular geranylgeranylation, with the substrate coming from plastids. S-Carvone, a monoterpene, was identified as an inhibitor of PPTS, resulting in a lack of capsidiol production. This work also suggests that a new mechanism of prenylation might exist, specifically in leaves.

Dissertation (Ph.D.)--University of South Florida, 2008. / Includes vita. Also available online. Includes bibliographical references.

Overall survival of the metastatic forms of epithelial derived cancers, especially head and neck squamous cell carcinomas (HNSCC), has not significantly improved even with the application of aggressive combined modality approaches incorporating radiation and chemotherapy. Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in HNSCC. We have previously demonstrated that the combination of lovastatin, a potent inhibitor of the mevalonate pathway, with EGFR tyrosine kinase inhibitors induced robust synergistic cytotoxicity. However, the use of high dose statins in our clinical trial was associated with significant toxicities including higher than anticipated rate of muscle pathologies. Our goal was to uncover novel downstream targets of the mevalonate pathway that may enhance the efficacy or limit toxicities of this novel combination therapeutic approach. In this study we have demonstrated that GGTI-298, an inhibitor of protein geranylgeranylation, through its ability to disrupt the actin cytoskeleton, inhibits EGFR dimerization and cellular trafficking. This novel mechanism targeting the EGFR has clinical implications as GGTI-298 in combination with tarceva, a clinically relevant EGFR inhibitor, showed enhanced cytotoxicity and inhibitory effects on EGFR activation and its downstream signaling.

Dissertation (Ph.D.)--University of South Florida, 2008. / Title from PDF of title page. Document formatted into pages; contains 187 pages. Includes vita. Includes bibliographical references.

Overall survival of the metastatic forms of epithelial derived cancers, especially head and neck squamous cell carcinomas (HNSCC), has not significantly improved even with the application of aggressive combined modality approaches incorporating radiation and chemotherapy. Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in HNSCC. We have previously demonstrated that the combination of lovastatin, a potent inhibitor of the mevalonate pathway, with EGFR tyrosine kinase inhibitors induced robust synergistic cytotoxicity. However, the use of high dose statins in our clinical trial was associated with significant toxicities including higher than anticipated rate of muscle pathologies. Our goal was to uncover novel downstream targets of the mevalonate pathway that may enhance the efficacy or limit toxicities of this novel combination therapeutic approach. In this study we have demonstrated that GGTI-298, an inhibitor of protein geranylgeranylation, through its ability to disrupt the actin cytoskeleton, inhibits EGFR dimerization and cellular trafficking. This novel mechanism targeting the EGFR has clinical implications as GGTI-298 in combination with tarceva, a clinically relevant EGFR inhibitor, showed enhanced cytotoxicity and inhibitory effects on EGFR activation and its downstream signaling.

Le tri et le transport efficace des hydrolases acides vers le lysosome jouent un rôle critique pour la fonction des cellules. Plus de 50 maladies humaines sont dues à des mutations des enzymes lysosomales, des protéines régulant des processus-clés du transport vers le lysosome ou des enzymes effectuant des modifications posttraductionnelles importantes pour la fonction du lysosome. L’objectif de cette thèse est d’identifier des protéines et des mécanismes permettant à la cellule de réguler le transport des enzymes vers le lysosome. Nous avons formulé l’hypothèse que des protéines mutées dans des maladies lysosomales et dont les fonctions étaient inconnues pouvaient jouer un rôle dans le transport vers le lysosome. Les céroïdes-lipofuscinoses neuronales forment une famille de maladies lysosomales rares mais sont aussi les maladies neurodégénératives infantiles les plus fréquentes. Plusieurs gènes impliqués dans les NCL encodent des protéines aux fonctions inconnues. Les travaux présentés dans cette thèse ont identifié la protéine « ceroid lipofuscinosis neuronal-5 » (CLN5) qui est localisée à l’endosome et au lysosome comme élément nécessaire au recrutement et à l’activation de rab7. Rab7 est une protéine Rab-clé qui contrôle le trafic à l’endosome tardif. Cette petite GTPase est impliquée dans le recrutement de retromer, un complexe protéique qui régule le trafic de l’endosome vers l’appareil de Golgi des récepteurs de tri lysosomal comme sortilin et le récepteur du mannose-6-phosphate. Dans les cellules où CLN5 est déplété, les récepteurs de tri lysosomal sont moins recyclés plus rapidement dégradés. En utilisant des expériences de photomarquage nous avons aussi pu démontrer que Rab7 est moins activées en l’absence de CLN5. Pour exécuter leur fonction les protéines rabs doivent être recrutée à la membrane et activées par l’échange d’une molécule de GDP pour une molécule de GTP. Le recrutement des Rabs à la membrane nécessite une modification posttraductionnelle lipidique pour être facilités. En utilisant un modèle de levures nous avons démontré que l’homologue de Rab7, Ypt7 est palmitoylée. Nous avons aussi démontré que la palmitoyltransférase Swif1 est nécessaire au recrutement de Ypt7 à la membrane. Nous avons aussi remarqué que les sous- unités de retromer chez la levure sont moins recrutées lorsque les palmitoyltransférases sont déplétées. Dans les cellules de mammifères nous avons démontré que Rab7 est également palmitoylé et que cette palmitoylation est possiblement effectuée par les palmitoyltransférases DHHC1 et DHHC8. La palmitoylation de Rab7 a lieu sur les cystéines en C-terminal qui sont nécessaires au recrutement membranaire et qui auparavant étaient uniquement décrites comme prénylées. En utilisant la méthode de « click chemistry » nous avons découvert que lorsque la prénylation de Rab7 est bloquée le niveau de palmitoylation augmente. Pour caractériser l’interaction entre CLN5 et Rab7 nous avons performé des expériences afin d’établir définitivement la topologie de cette protéine. Nous avons ainsi démontré que CLN5 est une protéine hautement glycosylée qui est initialement traduite en protéine transmembranaire et subséquemment clivée par un membre de la famille des peptidase de peptide signal (SPP). Cette protéine soluble peut alors possiblement interagir avec CLN3 qui est aussi palmitoylée pour recruter et activer Rab7. Nos études suggèrent pour la première fois que CLN5 pourrait être un recruteur et un activateur de Rab7 qui agirait avec la protéine CLN3 pour séquestrer Rab7 avec les autres récepteurs palmitoylés et permettre leur recyclage vers l’appareil de Golgi. / The proper sorting and trafficking of acid hydrolases plays a critical role in the normal function of cells. Over 50 known human diseases are caused by mutations of lysosomal enzymes, of proteins that regulate key processes of transport to the lysosome or of enzymes that perform posttranslational modifications which are important for the function of the lysosome. The main objective of this thesis is to identify proteins and mechanisms that allow the cell to regulate the transport of enzymes toward the lysosome. We formulated the hypothesis that proteins mutated in lysosomal diseases and that have no known functions could play a role in transport toward the lysosome. Neuronal ceroid-lipofuscinoses form a family of lysosomal storage disorders that are very rare but are also the most frequent infantile neurodegenerative diseases. The work presented in this thesis identified ceroid-lipofuscinosis neuronal-5 (CLN5), which is located at the late-endosomal/lysosomal compartment as a necessary element for the recruitment and activation of Rab7. Rab7 is an important GTPase that controls traffic from the late-endosome to the trans-Golgi network. Rab7 has been implicated in the recruitment of the retromer complex, which regulates retrograde transport of the lysosomal sorting receptor such as sortilin and the mannose-6-phosphate receptor. In the cells where CLN5 is depleted, the lysosomal sorting receptors are less recycled and degraded more rapidly. Using photolabelling assays we were also able to show that Rab7 is less activated in the absence of CLN5. To perform their function, Rab proteins have to be recruited to membranes and activated by the exchange of a GDP nucleotide for GTP. The recruitment of Rabs to membranes necessitates a lipidic posttranslational modification to raise the affinity. Using yeast as a model we demonstrated that the Rab7 homolog, Ypt7 is palmitoylated. We have also showed that the yeast palmitoyltransferase Swif1 is required for Ypt7 membrane recruitment. We have also observed that retromer subunits in yeast are less recruited when palmitoyltranferases are depleted. In mammals we have shown that Rab7 is also palmitoylated and that this palmitoylation may be done by palmitoyltransferases DHHC1 and DHHC8. The palmitoylation of Rab7 occurs on the C-terminal cysteines that are required for membrane recruitment and were previously only shown to be prenylated. By using Click chemistry we have discovered that when Rab7 prenylation is blocked the level of palmitoylation is augmented. To characterize the interaction of Rab7 and CLN5 we performed experiments to definitively establish the topology of this latter protein. Our results show that CLN5 is a heavily glycosylated protein that is initially translated as a type II transmembrane protein and subsequently cleaved by a member of the signal-peptide peptidase (SPP) family. This protein can then possibly interact with another member of the CLN family, CLN3 that is predicted to be palmitoylated to recruit and activate Rab7. Our studies establish for the first time that CLN5 is required for the recruitment and activation of Rab7 and may cooperate with the possibly palmitoylated protein CLN3 to sequester Rab7 in specific membrane domains with sorting receptors to allow their recycling toward the trans-Golgi network.